Cargando…
Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
COVID-19 has recently become a major pandemic with associated socioeconomic dimensions. Mortality statistics suggest that COVID-19 is more lethal in aged patients with comorbid conditions including hypertension. There is ongoing debate about whether the use of angiotensin converting enzyme (ACE) inh...
Autores principales: | Khan, Sikandar Hayat, Zaidi, Sabeen Khurshid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281700/ https://www.ncbi.nlm.nih.gov/pubmed/32837189 http://dx.doi.org/10.1007/s40267-020-00750-w |
Ejemplares similares
-
Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021) -
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020) -
Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020) -
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)